Tuesday, December 22, 2009
USA TODAY's Rita Rubin reports that researchers are investigating whether the same approach used to prevent infectious diseases could treat addictions to such drugs as nicotine.
Nabi Pharmaceuticals has gotten a $10-million grant to study the effectiveness and to monitor the side effects of a smoking-cessation vaccine. Nabi, based in Rockville, Md., expects to begin enrolling patients in the NicVax study by year's end.
0 Comments:
Subscribe to:
Post Comments (Atom)
